Share from 0:00
0:00
/
0:00
Transcript
Metsera's CEO Whit Bernard on the obesity space, including GLP-1s, amylin analogs, and how the company is also developing both as oral peptides
He describes how Metsera is aiming to develop a differentiated GLP-1 vs currently marketed products by having a lower dose and longer half-life. We discuss all the hot button issues.
BiotechTV
Authors
BiotechTV
Recent Posts
Share this post